TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01824108

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar discectomy
Description: All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar discectomy combined with Wallis interspinous dynamic stability system
Description: The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
Study: NCT00657397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone sirup once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone sirup once daily
Study: NCT02769000

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 10 GY in 5 daily fractions
Description: Subjects 1-15 10 GY in 5 daily fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 GY in 10 daily fractions
Description: Subjects 16-30 20 GY in 10 daily fractions
Study: NCT00811265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS for prostate cancer
Description: Simulated use of ExAblate MRgFUS system
Study: NCT04220034

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample will be collected to determine development or increase level frequencies of different types of autoantibodies in patients receiving ICI for the first time
Study: NCT02139085

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GSV Electrocoagulation
Description: The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GSV Radiofrequency
Description: The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
Study: NCT01789008

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of Advanced Fibrosis in Alcoholic Liver Disease

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Determination of Advanced Fibrosis in Alcoholic Liver Disease
Study: NCT00821522

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
Study: NCT01829295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: For the first two weeks, an introductory dose of 500 mg twice a day (BID) orally. After two weeks, the dose will be increased to 1.5 g BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
Study: NCT03182686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL injection of Ampion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL Injection of Placebo
Description: 4 mL Injection of Placebo
Study: NCT01213719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 20g/d throughout 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: betaine
Description: 2g/d throughout 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dextrose
Description: dextrose (placebo), 20 g/d throughout 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: creatine plus betaine
Description: creatine (20g/d) plus betaine (2g/d) throughout 10 days
Study: NCT00817466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racemic adrenaline
Description: For inhalation.~Dosing (as in previous study):~1) 0,1ml\<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml \>10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racemic adrenaline
Description: For inhalation.~Dosing (as in previous study):~1) 0,1ml\<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml \>10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: 2ml NaCl 9mg/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: 2ml NaCl 9mg/ml.
Study: NCT01866683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 month respiratory training
Description: Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 month respiratory training
Description: Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 month waiting period
Description: waiting or detraining period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 month waiting period
Description: waiting or detraining period
Study: NCT01154127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: 50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
Study: NCT01472692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: 80mg PO daily for 8 weeks
Study: NCT03308097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Mobile Messaging Intervention
Description: See group description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: See group description
Study: NCT00789854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: 300 mg once daily (od)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: 300 mg once daily (od)
Study: NCT01154127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: 50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
Study: NCT00789854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium carbonate
Description: 900 mg once daily (od)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI/Venlafaxine
Description: SSRI - doses within label, Venlafaxine dose up to 225 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI/Venlafaxine
Description: SSRI - doses within label, Venlafaxine dose up to 225 mg/day
Study: NCT03104140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental
Description: After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
Study: NCT04426058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP
Description: Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Illica
Description: Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
Study: NCT03032926

Intervention type: BEHAVIORAL
Intervention: Open Trial
Description: Behavioral Intervention
Study: NCT04145752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nurse-led femoral nerve block
Description: The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led femoral nerve block
Description: The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
Study: NCT01940237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Interpersonal psychotherapy in the treatment of major depressive disorder.
Study: NCT02717338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competence
Description: Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
Study: NCT02389309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT04577404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1186
Description: Treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period up to 96 weeks of treatment or until the drug is commercially available in that country.
Study: NCT02307942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric banding
Description: The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
Study: NCT04262999

Intervention type: OTHER
Intervention: effect of sodium valproate on alveolar bone level
Description: Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.

Intervention type: OTHER
Intervention: effect of levetiracetam on alveolar bone level
Description: Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.

Intervention type: OTHER
Intervention: effect of sodium valproate+levetiracetam on alveolar bone level
Description: Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.

Intervention type: OTHER
Intervention: control group
Description: Control group individuals will be systemically healthy.
Study: NCT01581762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided FNA
Description: EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: EUS-guided FNA
Description: EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
Study: NCT00267293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Given for fever control 15mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Given for fever control 15mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Given for fever control 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Given for fever control 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Given for fever control 10 mg/kg
Study: NCT00700869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: mechanical ventilation
Study: NCT04553692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplitabart (IGM-8444)
Description: DR5 Agonist Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplitabart (IGM-8444)
Description: DR5 Agonist Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplitabart (IGM-8444)
Description: DR5 Agonist Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplitabart (IGM-8444)
Description: DR5 Agonist Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplitabart (IGM-8444)
Description: DR5 Agonist Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplitabart (IGM-8444)
Description: DR5 Agonist Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aplitabart (IGM-8444)
Description: DR5 Agonist Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Chemotherapy Regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Chemotherapy Regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Chemotherapy Regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (and approved biosimilars)
Description: Targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (and approved biosimilars)
Description: Targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (and approved biosimilars)
Description: Targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birinapant
Description: SMAC-mimetic Investigational Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Targeted Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Chemotherapy
Study: NCT03755700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
Study: NCT02881463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutical exercises
Description: Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
Study: NCT02932384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention-Passport and Peer Mentor
Description: In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control-Passport Only
Description: A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control-Passport Only
Description: A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete.
Study: NCT02079922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
Study: NCT01866410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO